410P Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

E.L. Buchmeier; D. Spigel; B.C. Cho; K. Laktionov; J. Fang; Y. Chen; Y. Zenke; K.H. Lee; Q. Wang; R. Bernabe Caro; I. Okamoto; S. Sezgin Goksu; M. Ozguroglu; S. Novello; N. Reinmuth; L. Paz-Ares; H. Xiong; P. Chugh; W.C.V. Lai; S. Senan

doi:10.1016/j.esmoop.2026.106724

March 17, 2026ESMO OpenOpen Access

410P Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

View Full Paper

Ask AI

Bookmark

Share

Key Points

The research investigates treatment patterns and their effects on patient outcomes using durvalumab after chemoradiotherapy in SCLC.
Conducted a phase III clinical trial with a focus on consolidation therapy.
Evaluated safety and tolerability of obrixtamig and ezabenlimab in SCLC patients.
Reported adverse effects (AEs) related to treatments.
Obrixtamig and ezabenlimab exhibited manageable safety and tolerability.
Cytokine release syndrome was observed in 78% of participants.
Encouraging efficacy was more pronounced at higher doses of obrixtamig.

Implication

This phase III trial demonstrates the safety and efficacy of durvalumab in patients with limited-stage SCLC, suggesting an effective consolidation treatment approach.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Buchmeier et al. (2026) studied this question.

synapsesocial.com/papers/69be34f26e48c4981c67305a https://doi.org/10.1016/j.esmoop.2026.106724

View Full Paper

Ask AI

Bookmark

Share

410P Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

Key Points

Implication

Abstract

Discussion

Cite This Study

410P Subsequent treatment (tx) patterns and impact on patient (pt) outcomes in the phase III ADRIATIC study of consolidation durvalumab (D) after concurrent chemoradiotherapy (cCRT) in limited-stage SCLC (LS-SCLC)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from ESMO Open

Keep reading

More related papers

More from ESMO Open